Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera (NASDAQ: NTRA) will feature Prospera in 17 abstracts (six oral) at ISHLT 2026, highlighting heart and lung transplant applications. Key findings cite Prospera’s ability to predict 1-year adverse outcomes, influence clinical decisions in >30% of cases, reduce false positives with DQS, and detect CLAD, infection, and reflux-related injury.
Natera highlighted Allogene Therapeutics' interim futility analysis from the ALPHA3 trial (ALLO) on April 13, 2026. The analysis reported 58.3% MRD clearance with cema-cel and a median 97.7% ctDNA decrease at Day 45 versus a 26.6% median increase in observation.
The trial uses Natera's CLARITY MRD assay to randomize MRD-positive LBCL patients to cema-cel or observation; results are interim and final clinical outcomes remain pending.
Natera (NASDAQ: NTRA) said a Delaware federal judge on April 6, 2026 awarded Natera a 30% ongoing royalty on post-injunction revenues from infringing MRD-related product sales that fall within exceptions to a Nov 21, 2023 injunction.
The jury’s prior 20.5% effective royalty on pre-injunction revenues remains unchanged, and the court upheld validity of all three asserted MRD patents. Natera noted it holds over 650 issued or pending patents, including a portfolio of MRD patents.
Natera (NASDAQ: NTRA) will present 20 abstracts at AACR Annual Meeting April 17–22, 2026, spanning AI, ctDNA decision-making, MRD and real-world evidence.
Key data: models trained on >45,000 colorectal cases; AI AUROC 0.98 (MSI) and 0.93 (BRAF V600E); breast ML precision 93.5%/recall 91.1%; ctDNA study of 465 MSI-H metastatic CRC patients showed ~40% early ctDNA clearance and 3-year OS of 96% for early Signatera-negative patients.
Natera (NASDAQ: NTRA) published a prospective study in Clinical Cancer Research showing Signatera MRD testing identified older women with early-stage ER+/HER2- breast cancer who could forgo surgery and remain progression-free while receiving primary endocrine therapy (pET).
Key findings: 68% baseline MRD-negative (0 progressions), 100% baseline negative predictive value, and 100% longitudinal sensitivity for progression detection; 43 patients enrolled, monitored every 3–6 months.
Natera (NASDAQ: NTRA) reported two peer‑reviewed studies showing clinical utility of Signatera, its personalized ctDNA assay, in anal squamous cell carcinoma (ASCC) and locally advanced rectal cancer (LARC).
In ASCC (n=84), Signatera‑negative or cleared patients had 100% one‑year OS and PFS, while post‑CRT ctDNA‑positive patients showed worse one‑year outcomes (63% OS; 44% PFS). In LARC (n=220), Signatera positivity after neoadjuvant therapy predicted higher regrowth risk (HR 4.62; p=0.003) and much higher relapse (88.0% vs 11.5%; p<0.0001).
MyOme and Natera (NASDAQ: NTRA) launched the Zenith™ portfolio, a premium exome and genome testing solution integrating MyOme's long-read methylation analysis with Natera's clinical network.
Methylation analysis will be automatically added to all eligible rare disease exome and genome orders starting early Q2 2026, initially as targeted confirmation for select conditions.
Natera (NASDAQ: NTRA) announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay for rare disease diagnosis, on March 12, 2026.
Zenith uses a whole-genome backbone plus long-read sequencing confirmation to improve detection of hard-to-detect features like tandem repeat expansions. The launch follows an exclusive partnership with MyOme and leverages Natera's EMR integration, clinical support, and nationwide commercial footprint. The company cites 30 million Americans affected by rare disease, typical diagnostic journeys of 4–7 years, and a 2019 U.S. economic burden estimate of $997 billion to frame market need. Natera is presenting Zenith at the 2026 ACMG meeting to showcase platform performance and real-world utilization.
Natera (NASDAQ: NTRA) will present 11 abstracts at ASCO GU (Feb 26-28, 2026) showing Signatera MRD's potential across genitourinary cancers.
Key findings include 73–77% ctDNA clearance in MIBC, Signatera-negativity linked to high two-year bladder-intact EFS (88.6% and 91%), and complementary utDNA+ctDNA perioperative stratification.
Natera (NASDAQ: NTRA) reported strong fourth-quarter and full-year 2025 results with significant revenue, margin, volume, and cash improvements.
Total revenue was $665.5M in Q4 2025 (+39.8% YoY) and $2,306.1M for FY2025 (+35.9%). Gross margin improved to 66.9% in Q4 and 64.7% for FY2025. Tests processed rose ~15.0% for the year, and the company achieved a positive cash inflow of $107.6M for FY2025.